SCHEMBL23200095

SCHEMBL23200095

Cc1ccc(NC(=O)N(Cc2ccc(C)o2)C2CCCC2)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
UBE2M P61081 5/20 0.47
DCUN1D1 Q96GG9 5/20 0.47
GAA P10253 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPT P10636 3/20 0.40
HPGD P15428 2/20 0.40
KDM4E B2RXH2 2/20 0.40
PKM P14618 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TP53 P04637 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23199964 0.90 UBE2M (0.47) LMNAUBE2MDCUN1D1GAAALDH1A1
SCHEMBL23200071 0.88 LMNA (0.45) LMNAUBE2MDCUN1D1GAAALDH1A1
SCHEMBL23200144 0.88 UBE2M (0.50) LMNAUBE2MDCUN1D1GAAALDH1A1
SCHEMBL23200114 0.87 LMNA (0.44) LMNAUBE2MDCUN1D1GAAALDH1A1
SCHEMBL23699895 0.84 LMNA (0.56) LMNAUBE2MDCUN1D1GAAALDH1A1
SCHEMBL23200222 0.84 LMNA (0.51) LMNAUBE2MDCUN1D1GAAALDH1A1
SCHEMBL23200139 0.84 GAA (0.54) LMNAUBE2MDCUN1D1GAAALDH1A1
SCHEMBL23200224 0.84 ALDH1A1 (0.50) LMNAUBE2MDCUN1D1GAAALDH1A1
SCHEMBL23200154 0.84 LMNA (0.50) LMNAUBE2MDCUN1D1GAAALDH1A1
SCHEMBL23200204 0.84 LMNA (0.50) LMNAUBE2MDCUN1D1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210238139-A1 MODULATORS OF TRYPTOPHAN CATABOLISM E-THERAPEUTICS PLC (GB) 2021-08-05 US claimed
EP-3802503-A1 UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM E-Therapeutics plc (GB) 2021-04-14 EP claimed
US-20210238139-A1 MODULATORS OF TRYPTOPHAN CATABOLISM E-THERAPEUTICS PLC (GB) 2021-08-05 US disclosed
US-20210238139-A1 MODULATORS OF TRYPTOPHAN CATABOLISM E-THERAPEUTICS PLC (GB) 2021-08-05 US disclosed
EP-3802503-A1 UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM E-Therapeutics plc (GB) 2021-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238139-A1 MODULATORS OF TRYPTOPHAN CATABOLISM TPH1, KYNU, TPH2 LMNA 4541/4885UBE2M 3929/4885DCUN1D1 1039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.